Literature DB >> 16150717

Requirements for induction and maintenance of peripheral tolerance in stringent allograft models.

Masayuki Sho1, Koji Kishimoto, Hiroshi Harada, Mauren Livak, Alberto Sanchez-Fueyo, Akira Yamada, Xin Xiao Zheng, Terry B Strom, Giacomo P Basadonna, Mohamed H Sayegh, David M Rothstein.   

Abstract

Peripheral tolerance can be achieved in many but not all murine allograft models. The requirements for controlling more aggressive immune responsiveness and generating peripheral tolerance in stringent allograft models are unknown. Understanding these requirements will provide insight toward ultimately achieving tolerance in humans, which are also resistant. We now demonstrate that the combination of donor-specific transfusion, anti-CD45RB, and anti-CD154 uniformly achieves >90-d survival of BALB/c skin allografts on C57BL/6 recipients. Recipients exhibit marked hyporesponsiveness to alloantigen in vitro. In distinct contrast to less rigorous models, engraftment remains absolutely dependent on cytotoxic T lymphocyte antigen 4 signaling, even after grafts are healed, suggesting that prolonged engraftment cannot simply be attributed to more effective depletion of alloreactive T cells but is actively maintained by regulation. Concordantly, we show that both CD4 and CD8 regulatory cells are required and can transfer donor-specific tolerance to naïve recipients. Nonetheless, most recipients ultimately develop gradual graft loss (median survival time = 140 d), suggesting that alloreactive cells emerging from the thymus eventually overwhelm regulatory capacity. In agreement, adding thymectomy to the regimen results in permanent engraftment (>250 d) and donor-specific tolerance not observed previously in this model. These results highlight the potency of both CD4 and CD8 regulatory cells but also suggest that in stringent settings, regulatory T cell longevity and capacity for infectious tolerance compete with prolonged graft immunogenicity and thymic output. These results provide insight into the mechanisms of tolerance in stringent models and provide a rational basis for innovative tolerogenic strategies in humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16150717      PMCID: PMC1201597          DOI: 10.1073/pnas.0505070102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance.

Authors:  Y Li; X C Li; X X Zheng; A D Wells; L A Turka; T B Strom
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

2.  Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance.

Authors:  A D Wells; X C Li; Y Li; M C Walsh; X X Zheng; Z Wu; G Nuñez; A Tang; M Sayegh; W W Hancock; T B Strom; L A Turka
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

3.  CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment.

Authors:  X X Zheng; T G Markees; W W Hancock; Y Li; D L Greiner; X C Li; J P Mordes; M H Sayegh; A A Rossini; T B Strom
Journal:  J Immunol       Date:  1999-04-15       Impact factor: 5.422

4.  Regulatory T cell lineage specification by the forkhead transcription factor foxp3.

Authors:  Jason D Fontenot; Jeffrey P Rasmussen; Luke M Williams; James L Dooley; Andrew G Farr; Alexander Y Rudensky
Journal:  Immunity       Date:  2005-03       Impact factor: 31.745

5.  Rat CD8+ FOXP3+ T suppressor cells mediate tolerance to allogeneic heart transplants, inducing PIR-B in APC and rendering the graft invulnerable to rejection.

Authors:  Jiawang Liu; Zhuoru Liu; Piotr Witkowski; George Vlad; John S Manavalan; Luigi Scotto; Seunghee Kim-Schulze; Raffaello Cortesini; Mark A Hardy; Nicole Suciu-Foca
Journal:  Transpl Immunol       Date:  2004-12       Impact factor: 1.708

6.  Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner.

Authors:  N N Iwakoshi; J P Mordes; T G Markees; N E Phillips; A A Rossini; D L Greiner
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

7.  The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival.

Authors:  T A Judge; Z Wu; X G Zheng; A H Sharpe; M H Sayegh; L A Turka
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

8.  Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4.

Authors:  T G Markees; N E Phillips; E J Gordon; R J Noelle; L D Shultz; J P Mordes; D L Greiner; A A Rossini
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

9.  Specific suppression of T helper alloreactivity by allo-MHC class I-restricted CD8+CD28- T cells.

Authors:  Z Liu; S Tugulea; R Cortesini; N Suciu-Foca
Journal:  Int Immunol       Date:  1998-06       Impact factor: 4.823

10.  Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance.

Authors:  T Wekerle; M H Sayegh; J Hill; Y Zhao; A Chandraker; K G Swenson; G Zhao; M Sykes
Journal:  J Exp Med       Date:  1998-06-15       Impact factor: 14.307

View more
  18 in total

1.  Induction of transplantation tolerance to fully mismatched cardiac allografts by T cell mediated delivery of alloantigen.

Authors:  Chaorui Tian; Xueli Yuan; Peter T Jindra; Jessamyn Bagley; Mohamed H Sayegh; John Iacomini
Journal:  Clin Immunol       Date:  2010-05-08       Impact factor: 3.969

2.  Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice.

Authors:  Ying Wang; Geoffrey Camirand; Yan Lin; Monica Froicu; Songyan Deng; Warren D Shlomchik; Fadi G Lakkis; David M Rothstein
Journal:  J Immunol       Date:  2011-01-26       Impact factor: 5.422

Review 3.  CD4(+)Foxp3(+) regulatory T cell therapy in transplantation.

Authors:  Qizhi Tang; Jeffrey A Bluestone; Sang-Mo Kang
Journal:  J Mol Cell Biol       Date:  2011-12-14       Impact factor: 6.216

4.  Distinct strategies are required to suppress antigen-specific responses to genetically modified keratinocytes and fibroblasts.

Authors:  Soosan Ghazizadeh; Li T Huang; Weibing Zhang
Journal:  Mol Ther       Date:  2011-10-11       Impact factor: 11.454

Review 5.  Transplantation tolerance through mixed chimerism.

Authors:  Nina Pilat; Thomas Wekerle
Journal:  Nat Rev Nephrol       Date:  2010-08-31       Impact factor: 28.314

6.  IL-6 and TNF-alpha synergistically inhibit allograft acceptance.

Authors:  Hua Shen; Daniel R Goldstein
Journal:  J Am Soc Nephrol       Date:  2009-04-08       Impact factor: 10.121

Review 7.  Viewing immune regulation as it happens: in vivo imaging for investigation of regulatory T-cell function.

Authors:  Michael J Hickey; Zachary Chow
Journal:  Immunol Cell Biol       Date:  2017-04-19       Impact factor: 5.126

Review 8.  T-cell exhaustion in allograft rejection and tolerance.

Authors:  Edward B Thorp; Christian Stehlik; M Javeed Ansari
Journal:  Curr Opin Organ Transplant       Date:  2015-02       Impact factor: 2.640

9.  An age-specific CD8+ T cell pathway that impairs the effectiveness of strategies to prolong allograft survival.

Authors:  Wei Du; Hua Shen; Anjela Galan; Daniel R Goldstein
Journal:  J Immunol       Date:  2011-08-26       Impact factor: 5.422

10.  The blockade of T-cell co-stimulation as a therapeutic stratagem for immunosuppression: Focus on belatacept.

Authors:  Renaud Snanoudj; Carlos Frangié; Benjamin Deroure; Hélène François; Caroline Créput; Séverine Beaudreuil; Antoine Dürrbach; Bernard Charpentier
Journal:  Biologics       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.